<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00349492</url>
  </required_header>
  <id_info>
    <org_study_id>CRCST-L-0001</org_study_id>
    <nct_id>NCT00349492</nct_id>
  </id_info>
  <brief_title>A Study Comparing Etoposide/Cisplatin With Irinotecan/Cisplatin to Treat Extensive Disease Small Lung Cancer</brief_title>
  <official_title>Randomized, Phase III Trial Comparing Etoposide/Cisplatin (EP) With Irinotecan/Cisplatin (IP) in Patients With Previously Untreated, Extensive Disease (ED) Small Cell Lung Cancer (SCLC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Clinical Research Center for Solid Tumor, Korea</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Clinical Research Center for Solid Tumor, Korea</source>
  <brief_summary>
    <textblock>
      This study is a randomized, multi-center clinical trial. Patients are stratified according to
      performance status (ECOG 0, 1 vs 2) and institution. Patients are randomized to 1 of 2
      treatment arms.

      Arm A: Patients receive etoposide IV on days 1, 2, 3 and cisplatin IV on day 1. Courses
      repeat every 3 weeks Arm B: Patients receive irinotecan IV on days 1, 8 and cisplatin IV on
      day 1. Coursed repeated every 3 weeks

      Treatment in both arms continues for 6 courses in the absence of disease progression or
      unacceptable toxicity.

      Patients are followed every 3 months for 1.5 years
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2006</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>percent</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety profile</measure>
    <time_frame>percent</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">372</enrollment>
  <condition>Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>EP</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>etoposide + cisplatin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IP</intervention_name>
    <description>irinotecan+cisplatin</description>
    <arm_group_label>EP</arm_group_label>
    <other_name>irinotecan + cisplatin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically diagnosed small cell lung cancer

          -  Extensive disease (distant metastasis, contralateral hilar lymph node involvement, or
             cytologically confirmed malignant pleural effusion)

          -  If patients have brain metastasis with neurological symptom, they should be stabilized
             neurologically with prior radiotherapy or surgery for the brain metastasis (no
             neurologic symptom in progress and without further steroid treatment)

          -  No prior chemotherapy, immunotherapy, surgery or radiotherapy for small cell lung
             cancer (Local radiotherapy for brain or bone metastasis with symptom is permitted, in
             which case patients can be enrolled in this study when they have recovered from
             toxicity of radiotherapy)

          -  One or more measurable disease by RECIST criteria

          -  at least 18 years of age

          -  Performance status of 0, 1 and 2 on the Eastern Cooperative Oncology Group (ECOG)
             criteria

          -  Adequate hematologic (neutrophil count &gt;= 1,500/uL, platelets &gt;= 100,000/uL), hepatic
             (transaminase =&lt; upper normal limit(UNL)x2.5, bilirubin level =&lt; UNLx1.5), and renal
             (creatinine =&lt; UNL) function

          -  Informed consent from patient which conforms to Institutional Review Board

        Exclusion Criteria:

          -  History of cured basal cell carcinoma or cured uterine cervical malignancy except for
             carcinoma in situ within 5 years

          -  Medically uncontrolled serious heart, lung, neurological, psychological, metabolic
             disease

          -  Uncontrolled serious infection

          -  Enrollment in other study within 30 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dae Seog Heo, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Soonchunhyang University Bucheon Hospital</name>
      <address>
        <city>Bucheon-si</city>
        <zip>420-767</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yeungnam University Hospital</name>
      <address>
        <city>Daegu</city>
        <zip>705-717</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Daegu Catholic University Hospital</name>
      <address>
        <city>Daegu</city>
        <zip>705-718</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gyeongsang National University Hospital</name>
      <address>
        <city>Jinju</city>
        <zip>660-702</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam-Si</city>
        <zip>463-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kangbuk Samsung Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110-746</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yonsei Cancer Center</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul Veterans Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>134-791</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kangnam St.Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>137-040</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chung-Ang University Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>151-756</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul Municipal Boramae Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>156-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St.Vincent Hospital</name>
      <address>
        <city>Suwon</city>
        <zip>422-723</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 5, 2006</study_first_submitted>
  <study_first_submitted_qc>July 5, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 7, 2006</study_first_posted>
  <last_update_submitted>December 3, 2013</last_update_submitted>
  <last_update_submitted_qc>December 3, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 4, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Clinical Research Center for Solid Tumor, Korea</investigator_affiliation>
    <investigator_full_name>Hyeong-Seok Lim</investigator_full_name>
    <investigator_title>Dae Seog Heo, professor</investigator_title>
  </responsible_party>
  <keyword>Small Cell Lung Cancer</keyword>
  <keyword>Extensive Disease</keyword>
  <keyword>Chemotherapy</keyword>
  <keyword>Randomisation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Camptothecin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

